Description: TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
Home Page: www.telabio.com
TELA Technical Analysis
1 Great Valley Parkway
Malvern,
PA
19355
United States
Phone:
484 320 2930
Officers
| Name | Title |
|---|---|
| Mr. Antony Koblish | Co-founder, Pres, CEO & Director |
| Dr. E. Skott Greenhalgh Ph.D. | Chief Technology Officer |
| Mr. Peter C. Murphy | Chief Commercial Officer |
| Mr. Roberto E. Cuca J.D. | CFO & COO |
| Ms. Megan Smeykal | VP, Corp. Controller, Chief Accounting Officer & Principal Accounting Officer |
| Mr. D. Taylor Ocasio | Gen. Counsel |
| Mr. Christopher H. Smith | Sr. VP of Sales |
| Ms. Jennifer Lou Armstrong | Sr. VP of HR |
| Mr. Michael Leonard | Sr. VP of Technical Operations |
| Mr. Paul Talmo | Chief Strategic Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.798 |
| Price-to-Sales TTM: | 5.3206 |
| IPO Date: | 2019-11-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 123 |